Danaher to Acquire Biopharma Unit of GE LifeScience for $21.4B

Shots: 

• Danaher to acquire biopharma unit of GE Life Sciences (GE Biopharma), in all stock transaction making total deal value of $21.4 B. GE Biopharma to receive $21.4B, including $18B in cash and $3B as convertible preferred shares in Danaher
• The focus of the acquisition is to strengthen & advance Danaher’s life science portfolio using GE’s bioprocessing technologies in developing therapies
• GE Biopharma unit comprises of chromatography hardware, cell culture media, single-use technologies, development instrumentation and service for research and development of drugs in multiple therapy areas. The transaction is expected to close on Q4’19

Click here to read full press release/ article | Ref: Danaher Corporation | Image: Yahoo Finance